Abstract:An efficient method for the disulfide bond formation in peptides by the silylchloride-sulfoxide system is described. Methyltrichlorosilane in trifluoroacetic acid, in the presence of diphenylsulfoxide, is found to cleave various S-protecting groups of cysteine to form cystine directly within 10 to 30 min. No side reactions were observed with nucleophilic amino acids such as Met, His, or Tyr, except for Trp, under the reaction conditions of the silylchloride-sulfoxide treatment. A chlorination of the indole moiety of unprotected Trp, rather than the sulfur-sulfur bond formation, is a dominant reaction when the peptide containing unprotected Trp is treated with the chlorosilane-sulfoxide. However, the disulfide bond can be formed efficiently with no modification at the indole ring by the treatment of the peptide having formyl-protected Trp residue with the silylchloride-sulfoxide system. The formyl group is removed by a brief treatment at basic pH without affecting the disulfide bond formed by the silylchloride-sulfoxide treatment. Total synthesis of human insulin, a two chain peptide containing three disulfide bonds, was achieved unambiguously by sequential and selective formation of disulfide bonds in the protein for the first time. The key reaction in the synthesis is regioselective formation of three disulfide bonds separately using the silyl chloride method described above. Prior to the insulin synthesis, it was confirmed by the syntheses of double-disulfide peptides: b-hANP, unnatural parallel dimer of a-hANP, and human endothelin-1 that no disulfide exchange occurred during the silyl chloride treatment. Using three orthogonal thiol protecting groups, Trt, Acm, and But, three disulfide bonds of human insulin were efficiently constructed by the successive reactions using thiolysis, iodine oxidation, and the sily1 chloride method. Each reaction for the stepwise disulfide formation proceeded within 15 to 60 min with no polymeric product and no solubility problem. The synthetic human insulin had the correct structure and was indistinguishable from natural human insulin.

Single-Shot Solid-Phase Synthesis of Full-Length H2 Relaxin Disulfide Surrogates

Synthesis of A11Cys-B11Cys Disulfide Surrogates of H2 Relaxin Through an Intermolecular Native Chemical Ligation-Assisted Diaminodiacid Strategy.

Synthesis of A11 Cys -B11 Cys Disulfide Surrogates of H2 Relaxin through an Intermolecular Native Chemical Ligation-Assisted Diaminodiacid Strategy

Insulin and Its Single-Chain Analogue

Solid phase synthesis and structural analysis of novel A-chain dicarba analogs of human relaxin-3 (INSL7) that exhibit full biological activity

Chemical synthesis of peptides within the insulin superfamily

Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology

Exploring the Use of Helicogenic Amino Acids for Optimising Single Chain Relaxin-3 Peptide Agonists

Total Chemical Synthesis of Aggregation‐Prone Disulfide‐Rich Starfish Peptides

High-throughput screening campaign identifies a small molecule agonist of the relaxin family peptide receptor 4

A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity

Total Chemical Synthesis of Palmitoyl-Conjugated Insulin

Engineering and Characterization of a Long Half-Life Relaxin Receptor RXFP1 Agonist

A Cysteine-specific Solubilizing Tag Strategy Enables Efficient Chemical Protein Synthesis of Difficult Targets

Relaxin family peptides: structure–activity relationship studies

Advanced Insulin Synthesis by One‐pot/Stepwise Disulfide Bond Formation Enabled by S‐Protected Cysteine Sulfoxide

[Studies on development of disulfide bond forming reaction and the application to regioselective disulfide formation].

Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists

Human Gene 2 Relaxin Chain Combination and Folding.

Artificial disulfide-rich peptide scaffolds with precisely defined disulfide patterns and a minimized number of isomers.

Supramolecular Assembly of Cp1-11 Peptide and Insulin for Rapid-Acting Formulation